Most Viewed Articles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Most Viewed Articles

Evaluating Market Opportunities in Orphan Drugs

September 5, 2012

PTSM: Pharmaceutical Technology Sourcing and Management

Although serving niche areas, orphan drugs offer good market opportunities for pharmaceutical companies and their suppliers.

Merck KGaA to Reduce 10% of its German Workforce

September 5, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck KGaA has announced plans to eliminate 1100 jobs in Germany by the end of 2015—almost 10% of the company's 10,900 German positions.

Bristol-Myers Squibb Issues Voluntary Recall of Carmustine for Overfilled Vials

September 4, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Bristol-Myers Squibb has initiated a voluntary recall of 10 lots of BiCNU (carmustine for injection) previously manufactured by Ben Venue Laboratories, a former, third-party contract manufacturer for the company, to the user level.

2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole

September 2, 2012

Pharmaceutical Technology

A review of taints and odors in the pharmaceutical and consumer healthcare industries.

Correlating Product Lifecycle and Manufacturing Site Characteristics with Critical-to-Quality Product Deviations

September 2, 2012

Pharmaceutical Technology

MIT survey results address product and site characteristics that statistically correlate with quality performance.

Strategies for High Containment

September 1, 2012

Pharmaceutical Technology Europe

Experts share insight on facility design and operations for high-potency manufacturing.

Janssen Pharmaceuticals to Pay $181 Million in Multistate Consumer-Protection Suit

August 31, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Johnson & Johnson subsidiary Janssen Pharmaceuticals has announced a settlement and consent decree with 36 states and the District of Columbia in regards to previously disclosed allegations related to the company's marketing and promotional practices relating to Risperdal (risperidone).

EMA Deals with Manufacturing Deficiencies for Cancer Medicine

August 27, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency has recommended that the anticancer medicine DepoCyte be recalled from EU countries following the discovery of manufacturing deficiencies at Pacira Pharmaceuticals' San Diego site.

Pfizer and Mylan Partner to Develop Generic Drugs in Japan

August 27, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Pfizer and Mylan have agreed to establish an exclusive long-term collaboration to develop, manufacture, distribute, and market generic drugs in Japan. The products included in the collaboration are expected to be sold under the Pfizer brand with joint labeling.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here